Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

被引：0
|
作者：
Motzer, R. J. [1 ]
Escudier, B. [2 ]
Bukowski, R. [3 ]
Rini, B. I. [3 ]
Hutson, T. E. [4 ]
Barrios, C. H. [5 ]
Lin, X. [6 ]
Fly, K. [7 ]
Matczak, E. [8 ]
Gore, M. E. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Villejuif, France
[2] Inst Gustave Roussy, Immunotherapy Unit, Villejuif, France
[3] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[4] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[5] PUCRS Sch Med Hematol & Oncol, Porto Alegre, RS, Brazil
[6] Pfizer Oncol, Clin Stat, La Jolla, CA USA
[7] Pfizer Oncol, Oncol, New London, CT USA
[8] Pfizer Oncol, Oncol, New York, NY USA
[9] Royal Marsden Hosp NHS Trust, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70649-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [21] INTERPRETING OVERALL SURVIVAL (OS) RESULTS WHEN PROGRESSION FREE SURVIVAL (PFS) BENEFITS EXISTS IN TODAY'S ONCOLOGY LANDSCAPE - METASTATIC RENAL CELL CARCINOMA (MRCC) CASE STUDY
    Negrier, S.
    Tang, Y.
    Chen, C.
    Bycott, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 453 - 454
  • [22] Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database
    Fay, Andre Poisl
    Mckay, Rana R.
    Lin, Xun
    Sinnantov, Ronit
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Bergerot, C. D.
    Clark, K. L.
    Ashing, K. T.
    Almeida, L.
    Bergerot, P. G.
    Obenchain, R.
    Dizman, N.
    Hsu, J.
    Maia, M. C.
    Philip, E.
    Loscalzo, M.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) - a validation study
    Pond, G. R.
    Dietrich, M.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Updated results on long-term overall survival (OS) of the French randomized phase II trial TORAVA in metastatic renal cell carcinoma (mRCC) patients
    Bay, Jacques-Olivier
    Negrier, Sylvie
    Perol, David
    Gravis, Gwenaelle
    Chevreau, Christine
    Delva, Remy
    Blanc, Ellen
    Geoffrois, Lionnel
    Legouffe, Eric
    Ferlay, Celine
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Effect of the quality of the methodology on the relationship between progression-free survival (PFS) and overall survival (OS) in advanced colorectal cancer clinical trials.
    Garcia-Albeniz, X.
    Carrera, G.
    Feliu, J.
    Aparicio, J.
    Torres, F.
    Maurel, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).
    Levi, Francis
    Parganiha, Arti
    Karaboue, Abdoulaye
    Innominato, Pasquale F.
    Giacchetti, Sylvie
    Garufi, Carlo
    Dispersyn, Garance
    Focan, C. N. J.
    Iacobelli, Stefano
    Bjarnason, Georg A.
    Moreau, Thierry
    Dugue, Pierre Antoine
    Waterhouse, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [28] EFFECT OF REDUCTION OF CIRCULATING TUMOR CELLS (CTCS) ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER (MBC) PATIENTS
    Giuliano, M.
    Giordano, A.
    Handy, B. C.
    Ueno, N.
    Andreopoulou, E.
    Alvarez, R. H.
    Valero, V.
    Hortobagyi, G. N.
    Reuben, J.
    Cristofanilli, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 33
  • [29] Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T. E.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Long-term progression-free survival (PFS) and overall survival (OS) to pemetrexed (P) as single agent in metastatic urothelial carcinoma (MUC): A Spanish Oncology Genitourinary Group (SOGUG) systematic review
    Cervera Grau, J. M.
    Gonzalez-Billalabeitia, Enrique
    Ayala, Francisco
    Ballester Navarro, Inmaculada
    Lopez, Antonio
    Garde, Javier
    Juan Vidal, Oscar
    Manuel Satre, Jose
    Barrajon, Enrique
    Esquerdo, Gaspar
    Molins, Carmen
    Macia, Sonia
    Diego Rolfo, Christian
    Espinoza Venegas, Macarena Paz
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345